Four Companies to Know in Hungary
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Address: 1106 Budapest, Keresztúri út 30-38. Hungary,Hungary
Tel: +36 1 265-5555
Web: http://www.egis.hu/Default.aspx
EGIS Pharmaceuticals PLC is one of the leading pharmaceutical companies in Central Europe. Our most important activities are the production of pharmaceuticals and active pharmaceutical ingredients, pharmaceutical research and development, sales of finished products and active pharmaceutical ingredients.
Out of our three production facilities, two are in Budapest. One of them is seated in our headquarters, in Keresztúri Street, where Active Pharmaceutical Ingredients are made, and the other is in Bökényföldi Street, with our tablet, injection and packaging plants as well as commercial warehouses.
In our third facility, in Körmend, tablets, ointments, suppositories, solutions, syrups and aerosols are made and packaged.
Our production system meets the international GMP principles and the regulations of the Hungarian National Institute of Pharmacy.
Production of Active Pharmaceutical Ingredients
Production of active pharmaceutical ingredients is an important field in the activity of EGIS PLC (and its legal predecessors). As a result of professional experience accumulated through the efforts of the last decades and the continuous modernization of the facilities, competitiveness of the production of active pharmaceutical ingredients has been maintained as it is well proved by successful exports and the good results of the national and international official controls.
At present, in this field of activity approximately 50 different active pharmaceutical ingredients and their intermediates are produced a year. The wide scale of products can be characterized by the gradual renewal and replacement of individual products.
Production of active pharmaceutical ingredients has been able to respond to the challenges of quality assurance and environment protection of the recent past successfully. Thorough grounding and commitment of people working in this strategic field are an important part of the complex professional culture belonging to EGIS.
Pharmaceutical Research and Development
Our research activity is aimed at the development of generic pharmaceutical products offering high marketing potential, the chemical synthesis of putative original drug molecules, and testing of their pharmacological effects. Our research work focuses on drugs effective on cardiovascular diseases, disorders of the central nervous system, the respiratory and digestive systems. At the end of our business year, closed on 30th September 2009, the number of our registrations and marketing authorizations totalled up to 2222.
Sales of Finished Products and Active Pharmaceutical Ingredients
EGIS PLC is ranked third on the basis of the number of packages sold in the Hungarian market, and is placed fifth concerning our sales revenue.
72% of our sales revenue comes from our export activity. We export our finished products first of all to the Eastern regions like Russia, Central- and Eastern-European countries, and the CIS countries. As for the Western countries France and the UK are among our main markets for finished products, while France, the Netherlands, Japan and the United States are considered as the greatest markets for our active ingredients and intermediate export.
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Dr. Zsuzsanna Fürst, President of the Ethics Committee for Clinical Pharmacology, elaborates on the role and activities of the ethics committee, shares her insights on structural framework of the application…
Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of…
Irisz Lippai-Nagy, CEO of AmCham Hungary, shares insights on the drivers contributing to economic growth in Hungary, recent policies and reforms, the role of the association, and policy recommendations to…
Oliver Strommer, newly appointed executive director of the British Chamber of Commerce in Hungary (BCCH), introduces the Chamber and its refocused aim of becoming a more dynamic player in business…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to…
Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in…
Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that…
See our Cookie Privacy Policy Here